Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vir Biotechnology Inc VIR

Healthcare Biotechnology
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical... see more

Recent & Breaking News (NDAQ:VIR)

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results

Business Wire May 2, 2024

Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024

Business Wire April 30, 2024

Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors

Business Wire April 18, 2024

Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024

Business Wire April 11, 2024

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Business Wire March 5, 2024

Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences

Business Wire February 23, 2024

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire February 22, 2024

Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer

Business Wire February 20, 2024

Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024

Business Wire February 1, 2024

Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation

Business Wire December 13, 2023

Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference

Business Wire December 6, 2023

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD's The Liver Meeting® 2023

Business Wire November 13, 2023

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD's The Liver Meeting® 2023

Business Wire November 10, 2023

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500(TM)

Business Wire November 8, 2023

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Business Wire November 2, 2023

Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

Business Wire October 30, 2023

Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference

GlobeNewswire October 12, 2023

Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD's The Liver Meeting® 2023

GlobeNewswire October 11, 2023

Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023

GlobeNewswire October 5, 2023

Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

GlobeNewswire October 3, 2023